Clinical Trial Update: A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Tarceva (erlotinib) in patients with locally advanced, metastatic, or recurrent non-small cell lung cancer harboring EG…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-11-16